Invest in Hamilton

Hamilton’s life sciences ecosystem continues to attract world-class investment and industrial growth. On September 3, 2026, AtomVie Global Radiopharma celebrated the grand opening of its new purpose-built manufacturing facility, marking a historic milestone for Hamilton economic development. Located at 10 Aeropark Boulevard, the site serves as the largest single-site Contract Development and Manufacturing Organization (CDMO) facility in North America dedicated to radiopharmaceutical development.

The completion of this $160-million facility represents a massive vote of confidence in Hamilton’s commercial infrastructure and specialized talent pool. The 72,300-square-foot site is designed for low-to-high throughput production, delivering more than a tenfold increase in AtomVie’s previous manufacturing capacity. This physical expansion is driving immediate job creation in the region. The organization is actively growing its team of highly skilled professionals and targets a workforce of more than 200 employees by the end of this year as operations scale toward full capacity.

AtomVie’s trajectory is a direct testament to the strength of Hamilton’s research and innovation pipeline. The company is a distinctive spinout of the Centre for Probe Development and Commercialization (CPDC), a McMaster University-based Centre of Excellence established to advance Canada’s leadership in nuclear medicine. This lineage highlights the tangible economic benefits of Hamilton’s academic and clinical research institutions. When life sciences organizations invest in Hamilton, they integrate into an established network of scientific expertise and a collaborative environment that accelerates the commercialization of new technologies.

Operating from its new Hamilton base, AtomVie says it will seamlessly advance radiopharmaceuticals from early clinical development through commercial manufacturing. The company already boasts a proven track record, having manufactured over 1,000 cGMP batches and successfully delivered doses to patients across 28 countries and six continents with a 99% success rate. This new facility ensures that the next generation of precision cancer therapies will be produced and exported directly from Hamilton to the rest of the world.

The inauguration of the Aeropark Boulevard site clearly demonstrates Hamilton’s capacity to support high-throughput, advanced manufacturing. It provides a successful blueprint for future companies looking to capitalize on robust logistical infrastructure, top-tier scientific talent, and a municipality dedicated to sustained economic growth.